A Study of LY2140023 in Healthy Males and Females

A Particle Size Study of 3 Different Particle Size Test Tablet Formulations Compared to the Reference Tablet Formulation in Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01591330

Enrollment

Registered

2012-05-04

Start date

2012-04-30

Completion date

2012-08-31

Last updated

2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

The study will evaluate the effect of different particle size of LY2140023. The study involves 4 single doses of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth with a washout period of at least 3 days between doses. This study will last approximately 60 days not including screening. Screening is required within 30 days prior to study entry.

Interventions

DRUGLY2140023 Reference form

80-mg tablet administered orally

DRUGLY2140023 Test-Low

80-mg tablet administered orally

DRUGLY2140023 Test-Medium

80-mg tablet administered orally

DRUGLY2140023 Test-High

80-mg tablet administered orally

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* are overtly healthy males or females, as determined by medical history and physical examination * male participants: agree to use a reliable method of birth control during the study and for 3 months following the last dose of LY2140023 and agree not to donate sperm for 3 months following the last dose of LY2140023 * female participants: * female participants of child-bearing potential who test negative for pregnancy at screening and agree to use a reliable method of birth control for the duration of the study and for at least 3 months after the last dose of LY2140023 * female participants who are of non-childbearing potential (that is, postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or confirmed tubal occlusion \[not tubal ligation\]). Postmenopausal is defined as no menses for at least 1 year, or a plasma follicle stimulating hormone (FSH) value of \>40 milli-international units per liter (mIU/mL), unless the participant is taking hormone replacement therapy * have a body mass index (BMI) of 19 to 32 kilograms per meter squared (kg/m\^2), inclusive, at the time of screening * have clinical laboratory test results within normal reference ranges for the population or investigator site or results with acceptable deviations that are judged to be not clinically significant by the investigator * have venous access sufficient to allow for blood sampling as per the protocol * are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures * have given written informed consent approved by Lilly and the chosen ethical review board (ERB)

Exclusion criteria

* are currently enrolled in or have completed or discontinued within the last 90 days from a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * have known allergies to LY2140023, LY404039, related compounds, or any components of the formulation * are persons who have previously completed or withdrawn from this study or any other study investigating LY2140023 and have previously received the investigational product * have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study * have an abnormal blood pressure or pulse rate as determined by the investigator * have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data * have evidence or any history of significant active neuropsychiatric disease * have increased risk of seizures based on a history of: * one or more seizures (except for a single simple febrile seizure \[lacking focality and lasting less than 15 minutes, not associated with a central nervous system (CNS) infection or severe metabolic disturbance\] as a child between ages 6 months to 5 years) * head trauma with loss of consciousness or a post-concussive syndrome within 1 year or lifetime history of head trauma with persistent neurological deficit (focal or diffuse) * uncontrolled migraine or transient ischemic attack (TIA) within 1 year and/or stroke with persistent neurological deficit (focal or diffuse); uncontrolled migraine is defined as migraine attacks that produce headache lasting up to 72 hours and are often accompanied by associated symptoms (nausea, photophobia, and phonophobia) that impair well-being and disrupt social functioning; TIA is defined as mini-stroke caused by temporary disturbance of blood supply to an area of the brain, which results in a sudden, brief decrease in brain function * CNS infection with persistent neurological deficit (focal or diffuse) * brain surgery * electroencephalogram (EEG) with paroxysmal (epileptiform) activity (isolated spikes waves, repetitive bursts of sharp waves, paroxysmal activity, frank seizures, spike-wave complexes, or sharp-slow wave complexes, or as locally defined) * brain structural lesion, including developmental abnormalities, as determined by examination or imaging studies (except hydrocephalus treated by shunt or without neurological deficits). * show evidence or any history of known substance dependence or abuse at any time (according to Diagnostic and Statistical Manual of Mental Disorders \[DSM-IV\] diagnosis) or regularly use known drugs of abuse and/or show positive findings on urinary drug screening * show evidence of human immunodeficiency (HIV) virus infection and/or positive human HIV antibodies * show evidence of hepatitis C and/or positive hepatitis C antibody * show evidence of hepatitis B and/or positive hepatitis B surface antigen * are women with a positive pregnancy test or women who are lactating * intend to use over-the-counter (OTC) or prescription medication within 14 days prior to dosing of LY2140023 * have donated blood of more than 500 milliliters (mL) within the 3 months prior to screening, or plan to donate blood within the 3 months after the last dose * have an average weekly alcohol intake that exceeds 28 units per week (males) and 21 units per week (females), or are unwilling to stop alcohol consumption for 48 hours prior to check-in for each treatment period until discharge in each period (1 unit = 12 ounces \[oz\] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) * have a clinically significant abnormality in the neurological examination * participants judged prior to randomization to be at suicidal risk by the investigator * participants who are unwilling to refrain from tobacco- or nicotine-containing products while in the Clinical Research Unit (CRU) or are unable to abide by CRU restrictions * show evidence of pruritus or skin exfoliation * have an eosinophil count \> 1.5 x 10\^9 per liter (L) * show evidence of active renal disease or creatinine clearance (CrCl) less than 90 milliliters per minute (mL/min) (as calculated by the Cockcroft-Gault equation) * in the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics: Maximum Concentration (Cmax) of LY2140023	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Last Time Point of Measurable Concentration (AUC[0-tlast]) of LY2140023	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Maximum Concentration (Cmax) of LY404039 (Active Moiety)	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Last Time Point of Measurable Concentration (AUC[0-tlast]) of LY404039 (Active Moiety)	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose

Secondary

Measure	Time frame
Pharmacokinetics: Time of Maximum Observed Drug Concentrations (Tmax) of LY404039 (Active Moiety)	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Terminal Half Life (t1/2) of LY404039 (Active Moiety)	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2140023	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Volume of Distribution During the Terminal Phase (Vz/F) of LY404039 (Active Moiety)	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Apparent Total Body Clearance (CL/F) of LY404039 (Active Moiety)	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Terminal Half Life (t1/2) of LY2140023	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Apparent Total Body Clearance (CL/F) of LY2140023	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose
Pharmacokinetics: Volume of Distribution During the Terminal Phase (Vz/F) of LY2140023	Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose

Countries

United Kingdom

Participant flow

Participants by arm

Arm	Count
Overall Study All participants	35
Total	35

Withdrawals & dropouts

Period	Reason	FG000
Period 1	Adverse Event	1
Period 2	Adverse Event	1
Washout of at Least 3 Days	Withdrawal by Subject	1

Baseline characteristics

Characteristic	Overall Study
Age, Continuous	34.1 years STANDARD_DEVIATION 13.2
Body Mass Index (BMI)	24.73 kilograms per meter squared (kg/m^2) STANDARD_DEVIATION 3.7
Race/Ethnicity, Customized Black or African American	2 participants
Race/Ethnicity, Customized White	33 participants
Region of Enrollment United Kingdom	35 participants
Sex: Female, Male Female	17 Participants
Sex: Female, Male Male	18 Participants
Weight	71.71 kilograms (kg) STANDARD_DEVIATION 13.34

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —
other Total, other adverse events	17 / 35	15 / 33	12 / 32	16 / 32
serious Total, serious adverse events	0 / 35	0 / 33	0 / 32	0 / 32